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Background: Primary care is an important setting for smoking cessation interventions. There is evidence for the
effectiveness of tailored interventions for smoking cessation, and text messaging interventions for smoking
cessation show promise. The intervention to be evaluated in this trial consists of two components: (1) a web-based
program designed to be used by a practice nurse or other smoking cessation advisor (SCA); the program generates
a cessation advice report that is highly tailored to relevant characteristics of the smoker; and (2) a three-month
programme of automated tailored text messages sent to the smoker’s mobile phone. The objectives of the trial are
to assess the acceptability and feasibility of the intervention and to estimate the short-term effectiveness of the
intervention in increasing the quit rate compared with usual care alone.
Methods/design: The design is a two parallel group randomised controlled trial (RCT). 600 smokers who want to quit
will be recruited in up to 30 general practices in the East of England. During a consultation with an SCA, they will be
individually randomised by computer program to usual care (Control) or to usual care plus the iQuit system
(Intervention). At the four-week follow-up appointment, the SCA will record smoking status and measure carbon
monoxide level. There will be two further follow-ups, at eight weeks and six months from randomisation date, by
postal questionnaire sent from and returned to the study centre or by telephone interview conducted by a research
interviewer. The primary outcome will be self-reported abstinence for at least two weeks at eight weeks. A sample size
of 300 per group would give 80% power to detect an increase in quit rate from 20% to 30% (alpha = 0.05, 2-sided
test). The main analyses of quit rates will be conducted on an intention-to-treat basis, making the usual assumption
that participants lost to follow up are smoking.
Discussion: This trial will focus on acceptability, feasibility and short-term effectiveness. The findings will be used to
refine the intervention and to inform the decision to proceed to a pragmatic trial to estimate longer-term effectiveness
and cost-effectiveness.
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The intervention to be evaluated in the iQuit in Practice
trial consists of two components: (1) a web-based program
designed to be used by a practice nurse or other smoking
cessation advisor (SCA) in a consultation with a smoker;
the program generates a cessation advice report that is
highly tailored to relevant characteristics of the smoker;
and (2) a three-month programme of automated tailored
text messages sent to the smoker’s mobile phone. The
iQuit system is a potentially cost-effective approach that is
designed to enhance the effectiveness of the consultation,
without requiring SCAs to radically change the way they
advise and treat smokers and to provide continuing sup-
port to smokers during their quit attempt.
The following sections provide a justification for the
choice of setting (primary care/general practice) and for
the two components of the intervention (tailored advice
reports and tailored text messaging).
Primary care as a setting for smoking cessation
interventions
Primary care, and general practice in particular, is an im-
portant setting for smoking cessation interventions. In the
context of the National Health Service (NHS) Stop Smok-
ing Services, more smokers are treated in primary care
than in other settings [1]. Smokers can be identified from
practice records and recruited proactively into smoking
cessation programmes or trials of such interventions, for
example by a letter from the general practitioner (GP)
[2,3]. The guidelines on smoking cessation for health pro-
fessionals in the UK endorse an important role for prac-
tice nurses in encouraging smokers to stop and providing
advice and support [4]. A systematic review of nurse-
delivered interventions for smoking cessation found them
to significantly increase the likelihood of quitting com-
pared with a control or usual care [5]. Current guidance
from the National Institute for Health and Clinical Excel-
lence (NICE) recommends a number of effective interven-
tions for smoking cessation suitable for use in primary
care, including brief interventions, individual behavioural
counselling, pharmacotherapies and self-help materials
[6]. A recent trend in the UK is for health care assistants
(HCAs) to be given responsibility for delivering smoking
cessation advice and support, but to date no studies have
evaluated the effectiveness of interventions delivered by
this group of health professionals.
Tailored interventions for smoking cessation
Tailored interventions use data collected on or about an in-
dividual to make the information provided to the individual
(e.g. smoking cessation advice) more personally relevant
and therefore more likely to be attended to, read and
understood, and acted upon. A Cochrane review of self-
help interventions for smoking cessation [7] identified 25trials of materials tailored to the characteristics of individual
smokers, which overall showed a small benefit (N = 28,189;
RR 1.31, 95% CI 1.20 to 1.42). The evidence was strongest
for tailored materials compared to no intervention, but also
suggested that tailored materials are more effective than
standard materials.
A meta-analysis of computer-tailored interventions for
health behaviour change identified 32 studies in which a
group receiving a tailored intervention for smoking cessa-
tion was compared with a group receiving a non-tailored
intervention or assessment only (it is not stated whether all
these studies were randomised controlled trials) [8]. The
mean effect size (Hedges g) based on self-reported point
prevalence abstinence was 0.16 (95%CI 0.12 to 0.19,
p < .001), which the authors interpret as a small-to-medium
effect size; the mean quit rates at final follow-up were 20%
in the tailored intervention group versus 14% in the com-
parison group. The effect size for the subset of 16 studies
reporting prolonged abstinence outcomes (at 10 weeks,
6 months and 9 months) was 0.24 (95%CI 0.20 to 0.31,
p < .001), which the authors interpret as a large effect size.
We have conducted three trials of tailored cessation ad-
vice delivered by letters or reports sent through the post
[9,10] or via the web [11], with mixed results. Our first trial
showed that tailored advice letters had a small but useful
effect on quit rates at six months among those participants
(callers to a quitline) who were cigarette smokers at base-
line [9]. Our more recent trial of tailored advice reports,
conducted in primary care, found an effect on quit at-
tempts [10]; the findings for prolonged abstinence were
consistent with there being a small positive effect of the
intervention, though this was not statistically significant. In
the third trial, tailored advice delivered via the web was not
more effective than standardized (non-tailored) advice [11].
Text messaging for smoking cessation
Text messaging (also called short message service or
SMS) has become an increasingly important communi-
cation medium with 11 million text messages being sent
an hour in the UK [12]. The technology enables short
messages to be sent easily, quickly and inexpensively. In
the UK, mobile phone ownership is high and texting is
widely used. 92% of UK adults own a mobile phone [13].
In 2011, 58% of adults used text messages at least once a
day to communicate with friends and family. The aver-
age person in the UK sent 200 SMS text messages per
month in 2011 [13]. Mobile phone ownership varies by
age (98% of 16–24 year olds; 68% of those aged 65+)
[13] and by income (67% households in the lowest in-
come decile group reported ownership in 2010, com-
pared with 90% in the highest income decile group) [14].
Nevertheless, this medium provides a way of delivering
smoking cessation advice and support to people across
age and socioeconomic groups.
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programmes [15,16]. Studies have shown that SMS-based
smoking cessation programmes are generally feasible and
acceptable [17], but data on effectiveness, particularly in the
longer term, are limited. A Cochrane review [18] identified
four trials with at least a six-month follow-up, reported in
five papers [19-23]. Two of these trials evaluated a com-
bined internet and mobile phone programme and showed
evidence of effectiveness at 12 months [22,23]. The trials of
text messaging showed positive short-term results but no
evidence of longer-term effectiveness. Since that review was
conducted, a large trial of the txt2stop intervention in the
UK has been published, showing a positive effect on bio-
chemically verified continuous abstinence at six months
[24]. The intervention was also cost-effective [25].
The system we have developed differs from txt2stop in
that the text messages in the iQuit system are highly tai-
lored to the individual smoker using both information
collected at baseline via an online questionnaire and infor-
mation obtained subsequently from the smoker via two-
way texting (sometimes referred to as dynamic tailoring).
Unlike previous trials, iQuit in Practice will evaluate an
intervention in which tailored text messaging is used to
support smoking cessation among smokers treated in pri-
mary care.
Trial objectives
The objectives of the trial are:
1. To assess the acceptability of the intervention among
the Smoking Cessation Advisers and the participants.
2. To assess the feasibility of the intervention and of
aspects of the trial design and procedures.
3. To estimate the short-term effectiveness of the
intervention in increasing the quit rate compared with
usual care alone.
The findings will be used to modify the intervention and
to inform the decision to proceed to a pragmatic trial to
estimate longer-term effectiveness and cost-effectiveness.
Methods/design
Design of the study
The design is a two parallel group randomised con-
trolled trial (RCT) with 1:1 individual allocation compar-
ing usual care (Control) with usual care plus the iQuit
system (Intervention).
Participants
Inclusion/exclusion criteria
Patients are eligible for inclusion in the study if they meet
all of the following criteria: current smoker (usually smokes
at least one cigarette a day and has smoked in the seven
days prior to randomisation date); able to read English andcan provide written informed consent; wants to quit smok-
ing and is willing to set a quit date within the 14 days after
randomisation; aged 18 – 75 years; has a mobile phone and
is familiar with sending and receiving SMS text messages;
willing to participate in study and follow study procedures;
not currently enrolled in another formal smoking cessation
study or programme; not using nicotine replacement ther-
apy (NRT), bupropion (Zyban), varenicline (Champix) or
other pharmacotherapy at randomisation date.
Patients will be excluded if considered by their GP to
be unsuitable for the project for any reason, for example
people with severe mental impairment or severely or ter-
minally ill. Patients with co-morbidities such as chronic
obstructive pulmonary disease (COPD) or diabetes will
not be excluded from the study unless their GP con-
siders them unsuitable. In addition, a person living in
the same household as an existing trial participant will
not be excluded from participating in the trial if they
meet the inclusion/exclusion criteria.
Recruitment: practices
Participants will be recruited from general practices in
the East of England. Our previous studies [2,10] suggest
that 20 is a feasible minimum target number of partici-
pating smokers per practice. Given the proposed sam-
ple size of 600 smokers, if 20 smokers were recruited
from each practice, we would need 30 practices in total.
However, some practices may be able and willing to re-
cruit and treat more than 20 smokers, in which case
the total number of participating practices will be fewer
than 30, which would be desirable from a logistical
standpoint.
To be eligible for the trial, a practice must have at least
one SCA who has been trained to give level 2 smoking
cessation advice and who has received refresher training
within the last two years (or is willing to be trained to this
level). The SCA(s) must have internet access from a com-
puter in the consultation room and access to a printer.
The practice should not be participating in any other
smoking cessation research study. Preference will be given
to practices that are geographically accessible from the
study centre in Cambridge.
Recruitment: participants
Participants will be recruited by two methods:
1. Opportunistic recruitment. Patients who self-refer, or
who are referred via another health professional, to the
SCA for smoking cessation advice will be given (or sent
via post) a Participant Information Sheet (PIS) and
Participant Consent Form (PCF) by the practice
reception staff. Posters will be displayed in the practice
and study leaflets will be placed in the waiting area to
encourage self-referral.
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identify potential participants from smoking status data
collected in recent medical appointments. Recent
smokers are likely to be current smokers. A list of
potential participants will be generated from the
practice database by a member of the primary care
team. The list will then be pre-screened by a practice
clinician for eligibility. A random sample of those
eligible to participate will be selected and sent, via post
from the GP Practice, a covering letter from patient’s
GP providing information as to why they are being
written to (‘smoker’ status on practice database), details
of smoking cessation advice available to them, a leaflet
outlining the study, and a copy of the PIS and PCF.
The consent procedure will follow Good Clinical Prac-
tice guidelines [26]. If they have not already done so,
those interested in participating in the research will be
requested to phone or attend the practice to make an
appointment with the SCA. When potential participants
attend their initial appointment with the SCA, they
should already have received information regarding the
trial, as outlined above. This will ensure that participants
have had at least 24 hours to consider whether to take
part in the study. They will be asked whether they wish
to take part in the study, and their eligibility will be
checked by the SCA. If they have not received informa-
tion about the study prior to attending the consultation,
they will be given an information pack by the SCA and
invited to return at a later date.
Those who do not wish to participate, or who are ineli-
gible, will receive usual care. Screening forms will be com-
pleted to record non-personal details of those individuals
who are interested in taking part but found to be ineligible.
Interventions
Control
Although there are some variations in practice, ‘usual care’
offered by SCAs for smoking cessation in the East of
England typically consists of a brief discussion about smok-
ing habits and history, measurement of expired-air carbon
monoxide (CO), brief advice to quit (including the import-
ance of setting a quit date), options for pharmacotherapy, a
prescription, and arranging a follow-up visit or phone call.
This is referred to as ‘level 2’ smoking cessation advice [27].
Intervention
The intervention consists of usual care, as described above,
plus two components: a tailored advice report and a
programme of tailored text messages:
(i) Advice report
The 30-item iQuit online questionnaire includes questions
on the following: demographic factors; smoking habits andhistory, including cigarette consumption and length of lon-
gest previous abstinence; motivation and determination to
quit; reasons for quitting; dependence; self-image; pros and
cons of quitting; difficult situations; children; living with
other smokers; social support; and current health prob-
lems. During the consultation, the SCA will ask the partici-
pant the questions and enter their answers on the online
questionnaire. If the participant is allocated to the inter-
vention condition, the program will generate an advice re-
port on completion of the questionnaire. The SCA will
print out the report and give it to the smoker. The report,
which is approximately three A4 pages in length, contains
detailed advice on quitting that is highly tailored to the in-
dividual smoker using their responses to the questionnaire.
The content of the report is based on: relevant theories of
smoking cessation and behaviour change, including social
cognitive theory [28] and the perspectives on change
model [29]; the findings from a previous study of predic-
tors of quit attempts and success in a sample of callers to
the Quitline; input from the Quitline counsellors; and ‘re-
ceived wisdom’ about smoking cessation (e.g. the import-
ance of setting a quit date). The program can generate over
3300 million different reports.
(ii) Text messaging
This is a 90-day program of automated text messages sent
to the smoker’s mobile phone. The messages will start the
day before the quit date that the smoker sets during the
consultation with the SCA. The number of messages sent
each day will be 0, 1 or 2. In the later part of the program,
fewer messages will be sent (i.e. 0 messages will be sent on
a greater proportion of days). The messages are designed to
remind smokers about their quit attempt, to provide infor-
mation about reasons for quitting, to provide general en-
couragement, to increase and maintain motivation to quit,
to boost confidence and to remind smokers of difficult situ-
ations and how to cope with them.
A key feature of the system, which distinguishes it from
other texting systems for smoking cessation, is that the
messages are individually tailored using both the informa-
tion collected on the online questionnaire and additional
information obtained from the smoker during their quit
attempt about their smoking status. To obtain the latter
information, query messages will be sent to the participant
on two occasions during the 90-day period, to which they
can text either YES or NO. In addition to the scheduled
supportive and query messages, the smoker will also be
able to text HELP or SLIP to immediately receive a mes-
sage designed to provide support if he/she is tempted to
smoke (HELP) or has just had a lapse (SLIP). The smoker
can text STOP to stop receiving any further text messages.
The web-based program and advice report were piloted
in five general practices in Cambridgeshire. The nurses
were positive about the computer-based assessment and
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gagement with the smokers. Although using the program
increased the length of the consultation, the nurses
thought that it integrated well with the usual procedures
and said that they would continue to use the program if it
were available. The text messages have been developed
following extensive qualitative work with smokers, includ-
ing focus groups and individual interviews [17,30].
Training
SCAs will receive training on how to deliver the inter-
vention and the importance of collecting and recording
accurate and complete data from all participants. Train-
ing will also include other research skills including the
taking of informed consent and the issue of confidential-
ity within a research setting. In a one-to-one session
with one of the research team, designed to rehearse what
will happen in the consultation with the smoker, SCAs
will be trained to use the iQuit computer program by
completing the online questionnaire, to follow the re-
search protocol, to complete case report forms, and to
use a Smokerlyser (Bedfont) CO monitor and an audio
recorder. Follow-up training and ongoing support will
also be provided by the research team.
Procedure: initial consultation
Once the patient has consented to participate in the
study, the SCA will provide brief smoking cessation ad-
vice, as per usual practice. The participant is required to
set a quit date within the next 14 days. Expired-air CO
level will also be measured. The CO monitors will be
calibrated regularly by the study team.
During the consultation, the SCA will log on to the
web-based iQuit program via the practice computer using
a personal SCA identification number. The SCA will be
prompted to enter answers to the first set of questions
(Part 1) on the online questionnaire, as they complete it in
consultation with the participant. These questions, which
will be completed for all participants in the study, include
gender, age, cigarette consumption, longest period of ab-
stinence, strength of motivation and determination to quit
smoking, and quit date (which must be in the next 14
days). The SCA will also enter the participant’s CO level
on the questionnaire. This information will be used to
characterise the sample and to check the baseline compar-
ability of the intervention and control groups.
For those participants randomised to the Control group,
only the first set of questions on the online questionnaire
will be completed and no advice report will be generated.
For those participants randomised to the Intervention
group, the SCA will ask a second set of questions (Part 2)
and will enter the answers on the online questionnaire. The
17 questions in Part 2 include whether participants think of
themselves as addicted to smoking, most important reasonfor quitting, most difficult situation in which to resist
smoking, main advantage and main disadvantage of quit-
ting, whether they live with other adults who smoke,
whether they have any health problems linked with smok-
ing, and their mobile phone number. The answers to both
sets of questions (Part 1 and Part 2) will be used to gener-
ate the tailored advice report. The SCA prints out the re-
port and gives it to the smoker and then concludes their
routine support by arranging a prescription for NRT or
other pharmacological treatment, if appropriate, and arran-
ging a routine NHS follow-up visit four weeks from the
quit date. Some practices may also conduct interim follow-
up visits according to their standard practice.
During the baseline and four-week follow-up consulta-
tions, the SCA will manually complete case report forms
(CRFs). These will record data collected by the NHS
routinely for smoking cessation targets (including ethnic
group, occupation code, smoking cessation medications
prescribed, outcome) to allow comparison of study quit
rates with NHS reported rates. The SCA will manually
record the time at start and completion of the CRFs,
and the iQuit program will record the time taken to
complete the first and second set of questions on the
online questionnaire.
Participants randomised to the Intervention group will
be sent tailored text messages from a web server at the
study centre over a three-month period, starting the day
before their quit date. To cover any costs associated with
receiving and sending text messages for the study, inter-
vention participants will be sent a £5 voucher, posted
out with the eight-week follow-up questionnaire. Con-
trol participants will not be sent any text messages.
Audiotaping of consultations
SCAs will be asked to audiotape a sample of interven-
tion and control consultations. The tapes will be used to
assess the fidelity of the intervention and to describe the
content of ‘standard advice’. They will also provide data
on the time taken to deliver the intervention and stand-
ard advice.
Randomisation
Participating smokers will be randomised by the iQuit
computer program during the consultation such that a
particular SCA will see approximately equal numbers of
intervention and control participants i.e. individual level
randomisation stratified by SCA. The sequence will be
generated by a computer-based random number generator
using the method of random permuted blocks with block
sizes of four and six to make the sequence difficult to pre-
dict without leading to a major imbalance in numbers be-
tween intervention and control groups if a block is
incomplete at the end of recruitment. The allocation se-
quence will be stored on the web server database prior to
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not to the SCAs or participants. Allocation will be made
by the trial web server as soon as Part 1 of the question-
naire has been submitted. At this point, the SCA and the
participant will become unblinded to group allocation.Procedure: follow-up
All participants will have a routine NHS follow-up at
four weeks from quit date and two research follow-ups,
at eight weeks and six months from randomisation date.4-week follow-up
Before they leave their initial appointment with the SCA,
participants will be asked to make a follow-up appoint-
ment. This visit will occur approximately four weeks after
the participant’s quit date (-3 days or +14 days), as per
usual NHS practice for smoking cessation. The SCA will
record smoking status and other data collected by the
NHS routinely for smoking cessation targets. CO level will
also be measured. The SCA will also check contact details
for the eight-week and six-month follow-ups.
In some instances, practices may follow-up patients by
telephone or by postal questionnaire. The research team
will collect data on the type of follow-up conducted at four
weeks and any interim follow-ups conducted. If partici-
pants do not attend the practice for their scheduled follow-
up appointment, SCAs will be encouraged to contact them
and invite them to attend on an alternative date. Partici-
pants who do not attend a four-week follow-up appoint-
ment with the SCA at the practice will still be included in
the study for follow-up at eight weeks and six months.8-week follow-up
The eight-week follow-up will be via a postal questionnaire
sent directly to participants from the study centre. The
questionnaire will assess self-reported abstinence and the
acceptability and feasibility of the intervention by those
participants who received it. Non-responders (those whose
questionnaire has not been returned to the study centre
within 2 weeks) will be phoned by a research interviewer,
initially blinded to the participant’s group allocation (con-
trol or intervention). The participant will be given the op-
tion of completing the questionnaire over the phone or
completing and returning it by post (they will be sent an-
other copy if they need one). For the first option, if the par-
ticipant is unwilling to complete the full questionnaire over
the phone, only the smoking outcome questions will be
asked. If it is not possible to contact the participant by tele-
phone after six attempts, no further attempt will be made
to collect eight-week follow-up data from that individual;
however, they will still be included in the study for follow-
up at six months.6-month follow-up
The same procedure will be used for the six-month
follow-up. If it is not possible to contact the participant
after six attempts, he/she will be recorded as lost to
follow-up.
Questionnaire survey and interviews with intervention
deliverers
In order to assess the acceptability of the iQuit interven-
tion for those delivering the intervention and to assess
the feasibility of the intervention and aspects of the trial
design, SCAs will be invited to complete a postal ques-
tionnaire, providing feedback on the programme includ-
ing research elements such as practice support, audio
recording and managing paperwork. A sub-sample of
SCAs, consisting of nurses and HCAs from high and
low recruiting practices will be purposively sampled to
participate in semi-structured interviews to canvass their
views on participating in the study.
Interviews will be completed at the practice, last up to
one hour and be audio recorded and transcribed verbatim.
Outcome measures
Effectiveness
(i) Primary outcome measure
The primary outcome measure of effectiveness will
be self-report of being abstinent from smoking for at
least two weeks at eight-week follow-up from
randomisation date, as assessed by postal
questionnaire or telephone interview.
(ii)Secondary outcome measures
Secondary outcome measures will include:
(a)CO-verified self-report of being abstinent from
smoking at four-week follow-up from quit date for
at least two weeks, assessed at an appointment with
the SCA. (We will use the definition recommended
for use by local Stop Smoking Services in England
[31]: a CO reading that is assessed 25 to 42 days
from quit date and is less than 10 parts per million.)
(b)Self-reported prolonged abstinence (at least 3
months) at six-month follow-up from randomisation
date, assessed by postal questionnaire or telephone
interview. Because follow up will be conducted by
post and/or telephone call with a research
interviewer, we do not plan to validate self-reports at
six months [32]. Furthermore, it would be difficult
to bring participants into the surgery for an
additional CO measure at this time point. The main
alternative, obtaining saliva samples by post for
cotinine assay, has several disadvantages: it may
yield a low response rate; measuring cotinine at one
time point cannot validate prolonged abstinence;
smoking behaviour may change between the
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impossible to check whether a returned saliva
sample is from a particular participant – samples
may be substituted; and a significant proportion of
participants may still be using nicotine replacement
at follow up.
Feasibility
Measures for assessing feasibility will include: the propor-
tion of practices approached who agree to participate; the
proportion of smokers who respond to the proactive re-
cruitment letter; the number of smokers per practice
recruited into the study in a six-month period; response
rates to postal follow-up questionnaires; increase in length
of consultation.
Acceptability
(i) To the SCAs
SCAs’ evaluation of using the iQuit program, as
assessed by postal questionnaire (how easy was it to
use; how helpful they found it; how it could be
improved; would they continue to use it if it were
available).
(ii)To the participants (intervention group only)
(a)Participants’ evaluation of the printed advice
report, as assessed by postal questionnaire at
eight weeks (whether they kept the report; how
much of it they read; how clear, useful and
relevant the advice was; what they particularly
liked and disliked about the report).
(b)Participants’ evaluation of the text messaging
component, as assessed by postal questionnaires
at eight weeks and six months (e.g. how useful
and relevant they found the messages; whether
there were too many or not enough; whether
they covered the right topics; how the system
could be improved).
(c)Proportions of participants who used the HELP
and SLIP features; frequency of use.
(d)Proportion of participants who texted STOP to
stop receiving further messages; when they did
this (number of days into the program); why they
did this (assessed on 6-month follow-up
questionnaire).
Sample size, power and precision
This is a proof-of-concept trial designed to yield informa-
tion about the acceptability, feasibility and short-term ef-
fectiveness of the intervention, but not to give a definitive
answer to the question of whether the intervention is ef-
fective in the longer term.
For effectiveness, we have chosen to power the study on
outcome at eight weeks (self-reported abstinence for atleast 2 weeks at 8 week follow-up from randomisation
date). A sample size of 300 per group would give 80%
power to detect an increase in quit rate from 20% to 30%
(alpha = 0.05, 2-sided test).
The six-month outcome will provide valuable additional
information. For comparison between groups at six-month
follow-up, a 95% confidence interval will be calculated to
estimate the precision of the estimate of the difference in
quit rates. Assuming a six-month quit rate of 8% in the
control group, based on pooled rates observed in similar
control groups reported in a Cochrane review of self-help
[7], an observed increase of 5% in the six-month quit rate
from 8% to 13% (RR 1.65) would be estimated with an
accompanying 95% confidence interval having a width
of +/-5%, given the trial size of 600. Such an observed in-
crease would be borderline statistically significant, though
the trial is limited to having 51% power to detect a true
underlying difference of 5% as statistically significant and a
larger trial would be needed to distinguish reliably a true in-
crease from a Type 1 error. Importantly, if a 5% increase is
observed, then an underlying population relative risk of 1.5
or higher will be estimated to exist with posterior probabil-
ity 74%, using a Bayesian statistical approach where no
prior information is added to that obtained through the
trial. This probability will inform the decision of whether to
proceed to a larger, pragmatic trial; the 95% confidence
interval would then be used to inform the choice of a
plausible and worthwhile effect size from which to power
this trial with a primary outcome of six-month or 12-
month quit rate.
Statistical analysis
An analysis plan will be prepared by the study statistician
prior to analysis. The two groups will be compared using
chi-squared tests and logistic regression analysis for binary
outcome measures, and independent t-tests, analysis of
variance and linear regression analysis for continuous mea-
sures. All tests will be two-sided using an alpha of 0.05.
The main analyses of quit rates will be conducted on an
intention-to-treat basis, making the usual assumption that
participants lost to follow up are smoking, although we
will also conduct sensitivity analyses using a range of less
severe assumptions informed by available baseline and in-
terim data [33]. A further sensitivity analysis will involve
estimating the intervention effect allowing for clustering
of participant outcomes by household. As the mean clus-
ter size (participants per household) will be close to 1, the
results and conclusions are not expected to be materially
different from the main analysis. The intra-household cor-
relation coefficient will be estimated in order to inform
the design and sample size of any subsequent trial.
Proportions, such as many of the secondary outcomes of
acceptability and feasibility, and loss to follow up, will be
reported overall and for each arm and compared between
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Proportions that are defined in a single arm will be esti-
mated with an exact 95% confidence interval using the bi-
nomial distribution.
Additional analyses will include an examination of po-
tential effect modifiers (i.e. was the intervention more ef-
fective in particular subgroups of smokers?), predictors of
quit attempts and success in quitting, and a comparison
of study quit rates with NHS reported rates. The cost of
delivering the intervention will be assessed in terms of the
average length of the consultation in the two conditions.
Ethical approval
Ethical approval for the trial was granted by Cambridge-
shire 2 Research Ethics Committee (REC reference num-
ber: 09/H0308/87).
Discussion
The objectives of this trial are to assess acceptability, feasi-
bility and short-term effectiveness of the iQuit in Practice
intervention. The intervention needs to be acceptable to
the SCAs who deliver it (the tailored advice report) and to
the participants who receive it (the tailored advice report
and the tailored text messages). Acceptability to the SCAs
will be assessed by both postal questionnaires and semi-
structured interviews. These will also address aspects of
feasibility, along with measures such as the number of
smokers per practice recruited into the study in a six-
month period. Acceptability to the participants will be
assessed by postal questionnaires and by measures of how
they engage with the text messaging programme, for
example the proportion who opt to stop receiving
text messages.
With regard to effectiveness, we designed the trial to
maximise both internal and external validity. The partici-
pant will be randomised by computer program during the
consultation. The allocation sequence will not be accessible
to the SCAs or to the participants. However, as soon as the
participant has been randomised, both the SCA and the
participant will know which group the participant has been
allocated to. If the participant is allocated to the interven-
tion group, the SCA will ask the participant more ques-
tions and enter the answers on the online questionnaire.
They will then print out the tailored advice report and give
it to the participant. The content of the remainder of the
consultation should be identical for intervention and con-
trol participants. However, given that both SCA and par-
ticipant will become unblinded during the consultation, it
is possible that there will be systematic differences between
intervention and control conditions in the usual care com-
ponent in the later part of the consultation; for example,
SCAs may unwittingly or deliberately provide additional
advice to control participants to compensate for themhaving been allocated to this condition, or control partici-
pants may ask what advice they would have received had
they been allocated to the intervention group. Such effects
may dilute differences between groups. A sample of inter-
vention and control consultations will be audiotaped so
that the content of the consultations can be compared,
which may allow us to detect (though not prevent) this
possible source of performance bias.
Outcome assessment will be by postal questionnaire or
by telephone interview conducted by a research inter-
viewer. The interviewer will initially be blinded to the par-
ticipant’s group allocation, and the primary outcome will
be assessed at the start of the interview, but the inter-
viewer will become unblinded during the interview when
they ask about the intervention. Whether the primary out-
come is collected by questionnaire or interview, there is a
risk of bias when the outcome is based on self-report and
participants know their group allocation. Use of an object-
ive measure would in principle eliminate outcome assess-
ment bias. We carefully considered whether to try to
obtain saliva samples by post for cotinine assay, but de-
cided against this because it has several disadvantages; for
example, it may yield a low response rate.
In this trial, external validity is increased by using health
professionals (practice nurses and health care assistants)
rather than research staff to deliver the intervention (tai-
lored advice report) and the control intervention (usual
care) in a general practice setting and by employing min-
imal exclusion criteria for both practices and patients. The
tailored advice report component of the intervention was
designed to be easily integrated into a usual care consult-
ation and the text messaging component to be delivered
independently of the general practice setting.
The findings of the trial will be used to refine the
intervention and to inform the decision to proceed to a
pragmatic trial of effectiveness and cost-effectiveness.
Such a trial would include a more detailed assessment of
costs, and the primary outcome for effectiveness would
be assessed at 6 or 12 months. We would consider using
a cluster randomised design (with practice as the cluster)
instead of individual randomisation, and we would at-
tempt to minimise the time that the SCAs spend on re-
search procedures in the consultation and to reduce the
measurement burden for participants and SCAs.
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